Topic

Biotech Investment

A collection of 1 issue

H.C. Wainwright Rates Nuvalent 'Buy' with $110 Target

H.C. Wainwright initiates coverage on Nuvalent (NUVL) with a 'Buy' rating and $110 price target, highlighting its potential in transforming lung cancer treatment.